Replimune Group Inc
NASDAQ:REPL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (1.9), the stock would be worth $4.99 (168% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.7 | $1.86 |
0%
|
| 3-Year Average | 1.9 | $4.99 |
+168%
|
| 5-Year Average | 2.2 | $5.75 |
+209%
|
| Industry Average | 4.6 | $12.1 |
+551%
|
| Country Average | 2.5 | $6.65 |
+257%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Replimune Group Inc
NASDAQ:REPL
|
148.1m USD | 0.7 | -0.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -164 720.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.6B USD | -110.9 | 86.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.9B USD | 21.5 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
165.4B USD | 7.3 | 19.5 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -5 465.3 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.9B USD | 5.9 | 28.1 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79B USD | 2.5 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.5B EUR | 6.7 | 38.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.1B AUD | 2.3 | 30.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 18.2 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.5 |
| 70th Percentile | 4.8 |
| Max | 147 580.5 |
Other Multiples
Replimune Group Inc
Glance View
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. The company is headquartered in Woburn, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2018-07-20. The firm is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The firm applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The firm is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP1 (vusolimogene oderparepvec), RP2, and RP3. The firm is focused on Phase 2 clinical trials with its lead product candidate, RP1, in approximately 240 patients with a range of solid tumors.
